From 22 October the United States will suspend the de minimis exemption that has allowed low‑value parcels to clear customs with minimal paperwork. The change, which affects all international mail, will require extra data and a bond guarantee for shipments under $800. While the measure is not aimed specifically at Canadian drugs, anyone who relies on medicines bought north of the border could face delays, refusals or sharply higher costs. Critics warn that the shift jeopardises access for millions of Americans who already turn to Canadian pharmacies for cheaper prescriptions, a lifeline described by some as a matter of life and death.
What the new customs measure entails
The rule targets the long‑standing de minimis threshold, which previously let goods valued at less than $800 enter the United States duty‑free and with limited documentation. As of 22 October that exemption will be suspended indefinitely, meaning every low‑value parcel must now be accompanied by additional information and a financial bond. The stated aim is to improve tariff collection and curb illicit narcotics, but the broader effect will be felt on everyday items ranging from textiles to toys—and, crucially, on prescription medicines ordered from abroad.
According to a 2020 study published in JAMA Network, roughly 2.3 million Americans obtain their medication outside the United States, the majority sourcing from Canada. The administration insists the change is part of a wider push to lower drug prices, pointing to most‑favoured‑nation agreements with pharmaceutical firms and the discounted‑drug website TrumpRx. Federal data released this summer showed a 3.1 % year‑on‑year drop in US prescription drug costs, the steepest decline since 1963, though analysts note that multiple factors beyond presidential policy contributed to the fall.
Stories from those who rely on cross‑border prescriptions
Susan Hooper, a 75‑year‑old resident of Toledo, Ohio, has been on oxygen for 14 years and depends on two daily medicines that are unavailable domestically. “The issue is a matter of life and death for me,” she said. She obtains Theophylline, which relaxes her airways, and Foradil, a bronchodilator for asthma, through a Canadian pharmacy. Since the Trump administration imposed extra tariffs on Canada in August, Hooper has already felt the pinch: Theophylline, which once cost $85 including shipping, now runs $141, while Foradil has jumped from $151 to $273. She says she is scrambling to stockpile supplies before the new customs rule takes effect.
Ken Hunter, executive director of the Campaign for Personal Prescription Importation, warned that the financial strain could become unsustainable for many. His organisation’s August study of ten commonly imported medicines highlighted Eliquis, a blood thinner. A three‑month supply of 180 5‑mg tablets costs $565 when bought from a Canadian mail‑order service, but the same quantity retails for about $1,017 via Amazon Pharmacy and $1,029 through GoodRx. “I’ve had so many of our members calling me and telling me, ‘I don’t know what I’m going to do,’” Hunter said. “We really need someone to step forward and say, ‘We really need this to stop.’”
Political reactions and calls for a pause
The rule has drawn concern from both sides of the aisle. Three Florida Republicans—Aaron Bean, Gus M. Bilirakis and C. Scott Franklin—wrote to the administration urging that Customs and Border Protection and the Food and Drug Administration guarantee that Floridians seeking relief from high drug prices will not be inadvertently harmed. Florida operates its own federally authorised Canadian prescription‑drug importation programme, though that initiative has stalled.
More than 70 Democrats also sent a letter to health and immigration officials, asking that the rule be paused unless officials can assure that medicines intended for personal use will continue to enter the country. The letter declared, “Americans should not lose access to affordable medicines simply because the government has better information about packages entering the country.”
White House spokesperson Allison Schuster defended the administration’s stance, saying, “The Trump administration continues working to ensure Americans have access to low‑cost pharmaceuticals across the board,” and cited the most‑favoured‑nation deals as evidence of progress.
U.S. Customs and Border Protection did not respond to requests for comment on the impending change.
Why it Matters
The suspension of the de minimis exemption threatens to cut off a vital supply route for millions of Americans who depend on lower‑priced medicines from Canada. For patients like Susan Hooper, the shift is not merely an inconvenience—it could mean choosing between essential treatment and financial ruin. While the government frames the measure as a tool to curb illicit trade and improve tariff compliance, the collateral damage risks undermining broader efforts to reduce drug costs and protect vulnerable populations. Unless safeguards are put in place, the rule could exacerbate health inequities at a time when affordable healthcare remains a top concern for voters nationwide.
